Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis

NCT07047690 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT07047690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07047690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis
Lead sponsor
Galderma R&D
Phase
Phase 2
Overall status
Recruiting
Start date
February 20, 2026
Completion date
July 23, 2028
Enrollment
162 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis